<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23361">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01887613</url>
  </required_header>
  <id_info>
    <org_study_id>REG001</org_study_id>
    <nct_id>NCT01887613</nct_id>
  </id_info>
  <brief_title>Specified Drug Use-Results Survey of Regnite</brief_title>
  <official_title>Specified Drug Use-Results Survey of Regnite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the long-term safety and efficacy and the information on the
      proper use of Regnite® under conditions of daily clinical use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sleeping condition and severity of restless legs syndrome (RLS) were recorded at the start
      and during the treatment.  The treatment period is scheduled to last 52 weeks in principle.
      For patients completing or discontinuing the use of Regnite® within 52 weeks, follow up on
      the withdrawal and rebound syndrome will be conducted up to 4 weeks of completion or
      discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Safety such as occurrence of adverse drug reactions and lab-tests</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restless Leg Syndrome score</measure>
    <time_frame>Baseline and at 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression</measure>
    <time_frame>Baseline and at 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>Regnite group</arm_group_label>
    <description>Patients who receive Regnite</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regnite</intervention_name>
    <description>oral</description>
    <arm_group_label>Regnite group</arm_group_label>
    <other_name>gabapentin enacarbil</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with moderate to severe idiopathic restless legs syndrome
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with moderate to severe idiopathic restless legs syndrome

        Exclusion Criteria:

          -  Patients with a history of hypersensitivity to any ingredients in Regnite or
             gabapentin

          -  Patients with severely impaired renal function (creatinine clearance of less than 30
             mL/min)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Administration</last_name>
    <email>clinicaltrials_info@jp.astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Touhoku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 25, 2013</lastchanged_date>
  <firstreceived_date>June 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gabapentin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
